FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3088555433> ?p ?o ?g. }

• W3088555433 endingPage "e479" @default.
• W3088555433 startingPage "e472" @default.
• W3088555433 abstract "To identify putative biomarkers that may serve as quantifiable, biological, nonclinical measures of the pharmacodynamic effect of edaravone in amyotrophic lateral sclerosis (ALS) and to report real-world treatment outcomes.This is a prospective, observational, longitudinal, multicenter (up to 40 sites) US study (Clinicaltrials.gov; NCT04259255) with at least 200 patients with ALS who will receive edaravone for 24 weeks (6 cycles; Food and Drug Administration-approved regimen). All participants must either be treatment naive for edaravone or be more than 1 month without receiving any edaravone dose before screening. Biomarker quantification and other assessments will be performed at baseline (before cycle 1) and during cycles 1, 3, and 6. Selected biomarkers of oxidative stress, inflammation, neuronal injury and death, and muscle injury, as well as biomarker discovery panels (EpiSwitch and SOMAscan), will be evaluated and, when feasible, compared with biobanked samples. Clinical efficacy assessments will include the ALS Functional Rating Scale-Revised, King's clinical staging, ALS Assessment Questionnaire-40, Appel ALS Score (Rating Scale), slow vital capacity, hand-held dynamometry and grip strength, and time to specified states of disease progression or death. DNA samples will also be collected for potential genomic evaluation. The predicted rates of progression and survival, and their potential correlations with biomarkers, will be evaluated. Adverse events related to the study will be reported.The study is estimated to be completed in 2022 with an interim analysis planned.Findings may help to further the understanding of the pharmacodynamic effect of edaravone, including changes in biomarkers, in response to treatment." @default.
• W3088555433 created "2020-10-01" @default.
• W3088555433 creator A5003112399 @default.
• W3088555433 creator A5014335916 @default.
• W3088555433 creator A5015630437 @default.
• W3088555433 creator A5016753156 @default.
• W3088555433 creator A5020496827 @default.
• W3088555433 creator A5030730290 @default.
• W3088555433 creator A5031062952 @default.
• W3088555433 creator A5032745219 @default.
• W3088555433 creator A5036652104 @default.
• W3088555433 creator A5044584675 @default.
• W3088555433 creator A5057092035 @default.
• W3088555433 creator A5063095459 @default.
• W3088555433 creator A5068098432 @default.
• W3088555433 creator A5069001547 @default.
• W3088555433 creator A5069333808 @default.
• W3088555433 date "2020-09-23" @default.
• W3088555433 modified "2023-09-26" @default.
• W3088555433 title "Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS)" @default.
• W3088555433 cites W1573786554 @default.
• W3088555433 cites W1916888801 @default.
• W3088555433 cites W1978874104 @default.
• W3088555433 cites W1980605405 @default.
• W3088555433 cites W1991030758 @default.
• W3088555433 cites W2001961695 @default.
• W3088555433 cites W2004922200 @default.
• W3088555433 cites W2013720811 @default.
• W3088555433 cites W2026158140 @default.
• W3088555433 cites W2026406888 @default.
• W3088555433 cites W2029225256 @default.
• W3088555433 cites W2034454495 @default.
• W3088555433 cites W2043340127 @default.
• W3088555433 cites W2052542747 @default.
• W3088555433 cites W2055317912 @default.
• W3088555433 cites W2059534047 @default.
• W3088555433 cites W2060230550 @default.
• W3088555433 cites W2076915154 @default.
• W3088555433 cites W2079672852 @default.
• W3088555433 cites W2081879241 @default.
• W3088555433 cites W2094168427 @default.
• W3088555433 cites W2109355833 @default.
• W3088555433 cites W2110184140 @default.
• W3088555433 cites W2128167427 @default.
• W3088555433 cites W2178618172 @default.
• W3088555433 cites W2416127993 @default.
• W3088555433 cites W2517949748 @default.
• W3088555433 cites W2520147597 @default.
• W3088555433 cites W2530101855 @default.
• W3088555433 cites W2590887570 @default.
• W3088555433 cites W2616124858 @default.
• W3088555433 cites W2767195935 @default.
• W3088555433 cites W2785498211 @default.
• W3088555433 cites W2810936220 @default.
• W3088555433 cites W2897165775 @default.
• W3088555433 cites W2898499839 @default.
• W3088555433 cites W2921595875 @default.
• W3088555433 cites W2950589943 @default.
• W3088555433 cites W2969622819 @default.
• W3088555433 cites W3022230889 @default.
• W3088555433 cites W4252979096 @default.
• W3088555433 doi "https://doi.org/10.1212/cpj.0000000000000968" @default.
• W3088555433 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8382414" @default.
• W3088555433 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34476128" @default.
• W3088555433 hasPublicationYear "2020" @default.
• W3088555433 type Work @default.
• W3088555433 sameAs 3088555433 @default.
• W3088555433 citedByCount "1" @default.
• W3088555433 countsByYear W30885554332022 @default.
• W3088555433 crossrefType "journal-article" @default.
• W3088555433 hasAuthorship W3088555433A5003112399 @default.
• W3088555433 hasAuthorship W3088555433A5014335916 @default.
• W3088555433 hasAuthorship W3088555433A5015630437 @default.
• W3088555433 hasAuthorship W3088555433A5016753156 @default.
• W3088555433 hasAuthorship W3088555433A5020496827 @default.
• W3088555433 hasAuthorship W3088555433A5030730290 @default.
• W3088555433 hasAuthorship W3088555433A5031062952 @default.
• W3088555433 hasAuthorship W3088555433A5032745219 @default.
• W3088555433 hasAuthorship W3088555433A5036652104 @default.
• W3088555433 hasAuthorship W3088555433A5044584675 @default.
• W3088555433 hasAuthorship W3088555433A5057092035 @default.
• W3088555433 hasAuthorship W3088555433A5063095459 @default.
• W3088555433 hasAuthorship W3088555433A5068098432 @default.
• W3088555433 hasAuthorship W3088555433A5069001547 @default.
• W3088555433 hasAuthorship W3088555433A5069333808 @default.
• W3088555433 hasBestOaLocation W30885554331 @default.
• W3088555433 hasConcept C126322002 @default.
• W3088555433 hasConcept C143998085 @default.
• W3088555433 hasConcept C185592680 @default.
• W3088555433 hasConcept C197934379 @default.
• W3088555433 hasConcept C2779134260 @default.
• W3088555433 hasConcept C2779554857 @default.
• W3088555433 hasConcept C2780596555 @default.
• W3088555433 hasConcept C2781197716 @default.
• W3088555433 hasConcept C2781413609 @default.
• W3088555433 hasConcept C535046627 @default.
• W3088555433 hasConcept C55493867 @default.
• W3088555433 hasConcept C61943457 @default.

• next